Merus (NASDAQ:MRUS) Receives $86.70 Consensus Target Price from Analysts

Shares of Merus (NASDAQ:MRUS) have been given an average recommendation of “Buy” by the thirteen ratings firms that are presently covering the firm, Marketbeat reports. Eleven research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $86.70.

MRUS has been the subject of several analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $67.00 target price on shares of Merus in a report on Thursday, July 25th. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Merus in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Friday, November 1st. Lifesci Capital upgraded Merus to a “strong-buy” rating in a report on Monday, July 29th. Finally, Guggenheim increased their target price on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st.

Merus Price Performance

Shares of NASDAQ MRUS opened at $49.66 on Friday. Merus has a 1-year low of $22.26 and a 1-year high of $61.61. The business’s 50 day moving average is $51.05 and its two-hundred day moving average is $51.90. The stock has a market capitalization of $3.40 billion, a P/E ratio of -12.57 and a beta of 1.12.

Merus (NASDAQ:MRUS) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million for the quarter, compared to analysts’ expectations of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, equities research analysts anticipate that Merus will post -3.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRUS. Allspring Global Investments Holdings LLC bought a new stake in shares of Merus in the 1st quarter valued at about $72,000. nVerses Capital LLC raised its stake in Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,500 shares in the last quarter. US Bancorp DE purchased a new stake in Merus during the third quarter worth $103,000. SG Americas Securities LLC bought a new stake in Merus during the 1st quarter valued at $108,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 489 shares during the period. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.